Vomiting on Wegovy (semaglutide 2.4 mg): Incidence, Severity, and Realistic Expectations

How common is vomiting on Wegovy 2.4 mg?

The Wegovy label pools three randomized, double-blind, placebo-controlled trials: 2,116 adults took semaglutide 2.4 mg weekly for up to 68 weeks and 1,261 took placebo [1]. Vomiting was reported by 24% of the semaglutide group and 6% of the placebo group [1]. Nausea was more common at 44% versus 16%, and diarrhea at 30% versus 16% [1]. Around 73% of people on Wegovy reported at least one gastrointestinal reaction, against 47% on placebo [1]. Vomiting appears on the label's list of most common adverse reactions, meaning those seen in 5% or more of patients [1]. About 19% of the people in those pooled trials had type 2 diabetes [1].

The largest single trial behind the picture is STEP 1, which randomized 1,961 adults with obesity or overweight and no diabetes to semaglutide 2.4 mg weekly or placebo for 68 weeks [2]. In that trial, 4.5% of people on semaglutide stopped treatment because of a gastrointestinal event, versus 0.8% on placebo [2].

STEP 2 looked at adults who did have type 2 diabetes: 1,210 people, 68 weeks, with gastrointestinal adverse events reported by 63.5% on semaglutide 2.4 mg versus 34.3% on placebo [3].

Does vomiting increase at higher doses and in younger patients?

Two 72-week trials compared three doses in adults with obesity: 1,311 people took 7.2 mg, 304 took 2.4 mg and 303 took placebo [1]. Vomiting was reported by 22%, 16% and 6% respectively, and nausea by 39%, 35% and 13% [1]. Permanent discontinuation for adverse reactions was 5% on 7.2 mg, 5% on 2.4 mg and 2% on placebo, with gastrointestinal reasons accounting for 3%, 3% and 0.3% [1]. The label permits 7.2 mg only in adults who have tolerated 2.4 mg for at least 4 weeks and need more weight loss [1].

In the adolescent trial, 133 patients aged 12 to under 18 took semaglutide 2.4 mg and 67 took placebo for 68 weeks [1]. Vomiting was reported by 36% versus 10%, and nausea by 42% versus 18% [1].

The oral form differs in dose but not in the pattern. In a 64-week trial, 204 adults received Wegovy 25 mg daily tablets. The label says the types and frequencies of adverse reactions were similar to those for the injection, with severe gastrointestinal reactions in 2% versus 0% on placebo [1].

How often does vomiting end treatment?

The label reports vomiting as a single figure for each trial programme rather than a breakdown by grade, so the 24% is not split into mild, moderate and severe. What the label does separate out is severity at the level of gastrointestinal reactions as a whole: 4.1% of people on Wegovy 2.4 mg had a severe gastrointestinal reaction versus 0.9% on placebo [1].

Nausea was the most common individually listed reason for stopping treatment: 1.8% stopped because of nausea and 1.2% because of vomiting [1]. Overall, 6.8% of people on 2.4 mg and 3.2% on placebo stopped permanently for adverse reactions [1]. The most common reasons were nausea (1.8% versus 0.2%), vomiting (1.2% versus 0%) and diarrhea (0.7% versus 0.1%) [1]. Put plainly: about one in eighty people on Wegovy stopped because of vomiting, against none on placebo [1].

Label warnings that can involve vomiting

These label warnings can involve vomiting or the fluid loss that follows it.

Kidney injury from volume depletion. Acute kidney injury occurred in 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with existing kidney impairment and during dose titration, and often after gastrointestinal fluid loss [1]. The label says to monitor renal function in people reporting adverse reactions that could lead to volume depletion [1].

Pancreatitis. The label says to discontinue Wegovy if pancreatitis is suspected [1]. Symptoms may include persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting [1].

Slowed or blocked gut. Postmarketing reports in the label include ileus, intestinal obstruction, and severe constipation including fecal impaction [1].

Severe gastroparesis. Wegovy is not recommended in patients with severe gastroparesis, a statement that sits within the label's severe gastrointestinal reactions warning [1]. The label does not say that semaglutide causes gastroparesis.

What the label says about dose timing

The starting dose is 0.25 mg once weekly for 4 weeks, then 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, with maintenance from week 17 at 2.4 mg (or 1.7 mg), so each step lasts 4 weeks [1].

For a missed weekly injection, the label says to give the missed dose if the next scheduled dose is more than 2 days away. After two or more consecutive missed doses, re-escalation from a lower dose may be needed [1]. Semaglutide has an elimination half-life of about 1 week, and the drug stays in the body for roughly 5 to 7 weeks after the last 2.4 mg dose [1].